Biodexa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for oncology and central nervous system disorders. The company leverages a combination of small-molecule chemistry and biologics platforms to advance drug candidates from preclinical studies through clinical trials. Biodexa’s research efforts are focused on areas of high unmet medical need, including metastatic cancers and neurodegenerative diseases, and the organization actively seeks strategic partnerships to enhance its development pipeline.
Biodexa’s most advanced product candidate, BDX-101, is a targeted small-molecule inhibitor currently in Phase 2 clinical trials for the treatment of metastatic breast cancer. In parallel, the company is evaluating BDX-202, an antibody-drug conjugate designed to improve therapeutic selectivity in solid tumors, and BDX-303, a proprietary peptide therapy aimed at slowing progression of Alzheimer’s disease. In addition to its internal R&D programs, Biodexa offers contract research services and process development for biologics manufacturing, serving a range of pharmaceutical and biotechnology clients.
Founded in 2011 and headquartered in Cambridge, Massachusetts, Biodexa has established research facilities in Dublin, Ireland, and a manufacturing collaboration in Shanghai, China. The company completed its initial public offering on the NASDAQ in 2020 under the ticker BDRX, and it now operates across North America, Europe and Asia, with a focus on expanding its development partnerships and preparing for potential regulatory submissions in multiple jurisdictions.
Biodexa is led by President and Chief Executive Officer Dr. Angela Martinez, a pharmaceutical industry veteran with over two decades of experience in oncology drug development. The executive team also includes Chief Financial Officer John Reynolds and Chief Scientific Officer Dr. Michael Cheng, each bringing extensive expertise in corporate finance and translational research. Under their leadership, Biodexa aims to advance its clinical programs and drive long-term value by addressing critical gaps in patient care.
AI Generated. May Contain Errors.
